-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Oppenheimer Lowers Avalo Therapeutics (NASDAQ:AVTX) Price Target to $10.00
Oppenheimer Lowers Avalo Therapeutics (NASDAQ:AVTX) Price Target to $10.00
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) had its price objective decreased by investment analysts at Oppenheimer to $10.00 in a research note issued on Tuesday, Stock Target Advisor reports. Oppenheimer's price objective would indicate a potential upside of 72.41% from the company's current price.
Avalo Therapeutics Price Performance
NASDAQ:AVTX traded up $0.03 during trading hours on Tuesday, hitting $5.80. 11,743 shares of the company's stock traded hands, compared to its average volume of 41,421. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.84. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 5.23. The stock's fifty day moving average price is $4.92 and its two-hundred day moving average price is $5.19.
Get Avalo Therapeutics alerts:Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of AVTX. Leo Brokerage LLC acquired a new position in Avalo Therapeutics during the first quarter valued at $45,000. Assenagon Asset Management S.A. acquired a new position in Avalo Therapeutics in the 3rd quarter worth about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth about $506,000.
About Avalo Therapeutics
(Get Rating)Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Recommended Stories
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) had its price objective decreased by investment analysts at Oppenheimer to $10.00 in a research note issued on Tuesday, Stock Target Advisor reports. Oppenheimer's price objective would indicate a potential upside of 72.41% from the company's current price.
據Stock Target Advisor報道,在週二發佈的一份研究報告中,奧本海默的投資分析師將阿瓦洛治療公司(納斯達克:AVTX-GET評級)的目標價下調至10.00美元。奧本海默的目標價格將表明,該公司目前的價格可能上漲72.41%。
Avalo Therapeutics Price Performance
Avalo治療藥物的性價比
NASDAQ:AVTX traded up $0.03 during trading hours on Tuesday, hitting $5.80. 11,743 shares of the company's stock traded hands, compared to its average volume of 41,421. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.84. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 5.23. The stock's fifty day moving average price is $4.92 and its two-hundred day moving average price is $5.19.
納斯達克:AVTX週二在交易時段上漲0.03美元,觸及5.8美元。該公司有11,743股股票易手,而其平均成交量為41,421股。Avalo治療公司的12個月低點為2.42美元,12個月高位為27.84美元。該公司的速動比率為1.07,流動比率為1.07,債務權益比率為5.23。該股的50日移動均線價格為4.92美元,200日移動均線價格為5.19美元。
Institutional Inflows and Outflows
機構資金流入和流出
Several large investors have recently bought and sold shares of AVTX. Leo Brokerage LLC acquired a new position in Avalo Therapeutics during the first quarter valued at $45,000. Assenagon Asset Management S.A. acquired a new position in Avalo Therapeutics in the 3rd quarter worth about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after purchasing an additional 327,241 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after purchasing an additional 124,769 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics in the 2nd quarter worth about $506,000.
幾家大型投資者最近買賣了AVTX的股票。Leo Brokerage LLC在第一季度收購了Avalo治療公司的一個新頭寸,價值4.5萬美元。Assenagon Asset Management S.A.在第三季度收購了Avalo Treeutics的一個新頭寸,價值約5.2萬美元。復興技術公司在第一季度將其在阿瓦洛治療公司的地位增加了819.1%。復興科技有限責任公司在上個季度額外購買了327,241股後,現在擁有367,193股該公司股票,價值266,000美元。高盛公司在第二季度將其在阿瓦洛治療公司的頭寸增加了23.8%。高盛股份有限公司在上個季度增持了124,769股後,目前持有649,653股該公司股票,價值324,000美元。最後,Millennium Management LLC在第二季度獲得了Avalo治療公司的一個新職位,價值約506,000美元。
About Avalo Therapeutics
關於Avalo Treateutics
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家臨牀階段的精密藥物公司,為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002,這是一種完全人類抗光的單抗,正在進行第二階段臨牀試驗,用於治療非嗜酸性哮喘以及炎症性腸道疾病,包括中到重度克羅恩病和潰瘍性結腸炎;以及第三階段臨牀試驗,用於治療新冠肺炎急性呼吸窘迫綜合徵。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
- 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
- 不要追逐沃爾瑪更高,等待超低價格
- 家得寶的業績(和機構)是勞氏的催化劑嗎?
- 三隻細價股在11月大動干戈
- 安捷倫在下週第四季度報告發布前仍在買入區間
- WayFair仍有其公平份額的問題
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧